Each year, FDA consults with industry and the public to develop a list of regulatory science initiatives on generic drugs in accordance with the Generic Drug User Fee Amendments (GDUFA). These priorities are discussed and developed in public meetings and workshops and result in several awarded projects each year.
Research Priorities
GDUFA Regulatory Science Initiatives Public Workshops & Meetings
- FY2025 Generic Drug Regulatory Science Initiatives Public Workshop (June 3-4, 2025)
- FY2024 Generic Drug Regulatory Science Initiatives Public Workshop (May 20-21, 2024)
- FY2023 Generic Drug Regulatory Science Initiatives Public Workshop (May 11-12, 2023)
- FY2022 Generic Drug Regulatory Science Initiatives Public Workshop (May 9-10, 2022)
- FY2021 Generic Drug Regulatory Science Initiatives Public Workshop (June 23, 2021)
- FY 2020 Generic Drug Regulatory Science Initiatives Public Workshop (May 4, 2020)
- FY 2019 Generic Drug Regulatory Science Initiatives Public Workshop (May 1, 2019)
- FY 18 Generic Drug Research Public Workshop (May 24, 2018)
- FY 2017 Generic Drug Research Public Workshop (May 3, 2017)
- FY 2016 Regulatory Science Initiatives Part 15 Public Meeting (May 20, 2016)
- FY 2015 Regulatory Science Initiatives Part 15 Public Meeting (June 5, 2015)
- FY 2014 Regulatory Science Initiatives Part 15 Public Meeting (May 16, 2014)
- FY 2013 Regulatory Science Initiatives Part 15 Public Meeting (June 21, 2013)
Scientific Workshops & Meetings
- FDA and Center for Research on Complex Generics Co-Hosted Workshop: Regulatory Utility of Mechanistic Modeling to Support Alternative Bioequivalence Approaches (September 30 – October 1, 2021)
- SBIA 2021 Workshop- Advancing Generic Drug Development: Translating Science to Approval – Virtual Workshop (September 21-22, 2021)
- In Vitro Release Test (IVRT) and In Vitro Performance Test (IVPT) Methods: Best Practices, Regulatory Standards, and Scientific Considerations – Virtual CRCG Workshop (August 18-20, 2021)
- Upcoming: Advancing Innovative Science in Generic Drug Development Workshop (September 29-30, 2020)
- Complex Generic Drug Product Development Workshop (September 25-26, 2019)
- New Insights for Product Development and Bioequivalence Assessments of Generic Orally Inhaled and Nasal Drug Products (January 9, 2018)
- FDA-DIA Workshop on Complex Generic Drug-Device Combination Products (October 9-10, 2018)
- Complex Generic Drug Product Development Workshop September 12-13, 2018
- Overcoming Barriers to the Development of, and Improving Patient Access to, Topical Dermatological Generic Drug Products (October 20, 2017)
- Demonstrating Equivalence of Generic Complex Drug Substances and Formulations: Advances in Characterization and In Vitro Testing (October 6, 2017)
- Leveraging Quantitative Methods and Modeling to Modernize Generic Drug Development and Review (October 2-3, 2017)
- Oral Absorption Modeling and Simulation for Formulation Development and Bioequivalence Evaluation Workshop (May 19, 2016)
Awarded Projects
GDUFA Implementation
- Bi-Annual Industry Regulatory Science Work Group Meeting – August, 28, 2024
- Bi-Annual Industry Regulatory Science Work Group Meeting – November 17, 2023
- Bi-Annual Industry Regulatory Science Work Group Meeting – August 30, 2023
- Bi-Annual Industry Regulatory Science Work Group Meeting – December 8, 2022
- Bi-Annual Industry Regulatory Science Group Meeting – March 23, 2022
- Bi-Annual Industry Regulatory Science Group Meeting – September 24, 2021
- Bi-Annual Industry Regulatory Science Group Meeting – March 12, 2021
- Bi-Annual Industry Regulatory Science Group Meeting – February 10, 2020
- Bi-Annual Industry Regulatory Science Work Group Meeting – September 17, 2019
- Bi-Annual Industry Regulatory Science Work Group Meeting – February 25, 2019
- Bi-Annual Industry Regulatory Science Work Group Meeting – November 1, 2018
- Bi-Annual Industry Regulatory Science Work Group Meeting – April 10, 2018
-
Content current as of:
05/21/2025
